These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 37575230)

  • 1. Rituximab resistance in ITP and beyond.
    Xiao Z; Murakhovskaya I
    Front Immunol; 2023; 14():1215216. PubMed ID: 37575230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
    Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
    Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cells and antibodies in refractory immune thrombocytopenia.
    Roeser A; Lazarus AH; Mahévas M
    Br J Haematol; 2023 Oct; 203(1):43-53. PubMed ID: 37002711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine and rituximab in refractory immune thrombocytopaenia: A case series.
    Choy J; Swe EPP; Shearer A
    Vox Sang; 2022 Apr; 117(4):601-605. PubMed ID: 34939200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
    Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
    Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
    J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
    Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
    Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.
    Aleem A; Alaskar AS; Algahtani F; Rather M; Almahayni MH; Al-Momen A
    Int J Hematol; 2010 Sep; 92(2):283-8. PubMed ID: 20640541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab and Dexamethasone Combined with Cyclophosphamide for Treatment of Relapsed and Refractory Immune Thrombocytopenia].
    Han XD; Zhou J; Yu FK; Fang BJ; Zhang YL; Wei XD; Song YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):162-6. PubMed ID: 26913414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
    Lv Y; Shi H; Liu H; Zhou L
    Front Immunol; 2022; 13():953716. PubMed ID: 36003388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
    Oved JH; Lee CSY; Bussel JB
    J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study.
    Mageau A; Bonnotte B; Ebbo M; Dossier A; Galicier L; Souchaud-Debouverie O; Orvain C; Gerfaud-Valentin M; Gobert D; Riviere E; Audia S; Mahevas M; Michel M; Viallard JF; Godeau B
    Platelets; 2023 Dec; 34(1):2200848. PubMed ID: 37128870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and significance of large granular lymphocytes in patients with immune thrombocytopenia.
    Gabe C; Liu Y; Duncan J; St John M; Lucier KJ; Kimmel D; Kelton JG; Arnold DM
    Platelets; 2023 Dec; 34(1):2144194. PubMed ID: 36458562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.
    Journeycake JM
    Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenence rituximab following induction in autoimmune cytopenias.
    Rai MP; Lee EJ; Bussel JB
    Br J Haematol; 2023 Jul; 202(1):153-158. PubMed ID: 37086173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
    Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
    Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study.
    Sun F; Chen J; Wu W; Geng S; Xu W; Sun S; Chen Z; Gu L; Wang X; Li T; Ye S
    Clin Rheumatol; 2020 Oct; 39(10):3099-3104. PubMed ID: 32418039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.